Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain cell injection trial offers hope for rare Parkinson's-like disease

NCT ID NCT07289477

Recruiting now Disease control Sponsor: iRegene Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated May 24, 2026 · Updated 24 times

Summary

This early-stage trial tests a single injection of special brain cells (dopaminergic progenitor cells) into a specific area of the brain for people with Multiple System Atrophy (MSA), a rare and severe neurological disorder. The main goal is to check if the procedure is safe and tolerable in 9 adults aged 30-70 whose current treatments are not working well enough. Researchers will also look for signs that the treatment might help control symptoms over a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P) MULTIPLE SYSTEM ATROPHY - PARKINSONIAN SUBTYPE (MSA-P)